Compare Cintas Corporation (CTAS) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Cintas Corporation trades at $202.61 (market cap $79.86B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Cintas Corporation is far larger — about 3.2× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 125 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| CTAS | RPRX | |
|---|---|---|
Market Cap | $79.86B | $25.27B |
Volume | 1,323,583 | 3,671,183 |
Sector | Industrials | Health |
52-Week High | $216.53 | $63.96 |
52-Week Low | $163.55 | $35.44 |
Typical Hold Time | 125 Days | 1 Days |
Enterprise Value | $82.33B | $32.50B |
Dividend Yield | 1.03% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $202.41, up 2.65% on the day, reflecting strong momentum after recent earnings beat. The stock exhibits a bullish technical setup with price above key moving averages. Fundamentally, the company reported Q1 2027 revenue of $3.01 billion, a 10.9% YoY increase, with earnings per share of $1.39 surpassing estimates. Robust profitability is evident with a net income margin of 17.82% and ROE of 41.25%. Recent news highlights raised fiscal 2027 guidance, signaling management confidence in continued growth driven by organic expansion and margin gains.
The outlook for CTAS remains positive, supported by consistent revenue growth, high profitability, and bullish analyst sentiment with a consensus price target of $234.60. Key opportunities include sustained demand for uniform rental and workplace services, while risks involve elevated valuation multiples and potential economic sensitivity. The stock's current trajectory suggests further upside if execution remains strong, though investors should monitor margin sustainability and competitive pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
